# US 2026/0209839 A1 · Methods of Sequencing Polypeptides and Related Compositions

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0209839 A1
- Document ID: US20260209839A1
- Status: Published application
- Kind: A1
- Application number: 19/157,870
- Filed: 2024-02-23
- Published: 2026-07-23
- Earliest claimed: 2023-02-24
- Assignees: The Board of Trustees of the Leland Stanford Junior University
- Applicants: The Board of Trustees of the Leland Stanford Junior University
- Inventors: Hyongsok Soh; Liwei Zheng; Yujia Sun; Brandon Wilson; Joseph Buonomo
- Web page: https://patentgrep.com/patent/US20260209839A1

## CPC

- C12Q 1/6869: Methods for sequencing
- C40B 70/00: Tags or labels specially adapted for combinatorial chemistry or libraries, e.g. fluorescent tags or bar codes
- C12Q 1/6804: Nucleic acid analysis using immunogens (immunoassay G01N33/53)
- C12Q 1/682: Signal amplification
- G01N 33/6818: {Sequencing of polypeptides}
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C40B: COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES (in silico combinatorial libraries of nucleic acids, proteins or peptides G16B35/00; in silico combinatorial chemistry G16C20/60)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Provided are methods of sequencing a polypeptide. In certain embodiments, the methods comprise labeling the N-terminal amino acid of a polypeptide with a nucleic acid label comprising a unique molecular identifier and cycle number barcode; degrading the N-terminal amino acid from the polypeptide; annealing a primer to the nucleic acid label of the degraded amino acid, where the primer comprises a barcode corresponding to the identity of the degraded N-terminal amino acid; and extending the primer annealed to the nucleic acid label to produce an extension product comprising the unique molecular identifier, the cycle number barcode, and the barcode corresponding to the identity of the degraded N-terminal amino acid. The preceding steps are performed successively to produce a plurality of such extension products which are then sequenced, enabling determination of the amino acid sequence of the polypeptide. Composition and kits that find use in practicing the methods are also provided.

## Claims

### Claim 1

A method of sequencing a polypeptide, the method comprising:
(a) labeling the N-terminal amino acid of a polypeptide with a nucleic acid label comprising a unique molecular identifier (UMI);
(b) degrading the N-terminal amino acid from the polypeptide;
(c) annealing a primer to the nucleic acid label of the degraded N-terminal amino acid, wherein the primer comprises a barcode corresponding to the identity of the degraded N-terminal amino acid;
(d) extending the primer annealed to the nucleic acid label to produce an extension product comprising the UMI and the barcode corresponding to the identity of the degraded N-terminal amino acid;
(e) performing steps (a)-(d) in successive cycles to produce a plurality of extension products, each of the plurality of extension products comprising the UMI, a respective cycle number barcode, and a barcode corresponding to the identity of a respective degraded N-terminal amino acid;
(f) sequencing the plurality of extension products; and
(g) determining a sequence of the polypeptide based on the sequences of the plurality of extension products.

### Claim 2 (depends on 1)

The method of claim 1, comprising indexing the extension product produced at step (d) with the cycle number barcode.

### Claim 3 (depends on 1)

The method of claim 1, wherein step (a) comprises labeling the N-terminal amino acid of the polypeptide with a nucleic acid label comprising the UMI and the cycle number barcode.

### Claim 4 (depends on 1, 2, 3)

The method according to any one of claims 1-3, wherein prior to step (a), the polypeptide is immobilized on a solid support via a nucleic acid attached to the C-terminus of the polypeptide and the surface of the solid support, wherein the nucleic acid comprises the UMI and a primer binding site 3′ or 5′ to the UMI.

### Claim 5 (depends on 4)

The method according to claim 4, wherein the labeling step (a) comprises:
(i) conjugating a degradation moiety to the N-terminal amino acid;
(ii) conjugating a primer to the degradation moiety, wherein the primer conjugated to the degradation moiety comprises a sequence which is complementary to the primer binding site of the nucleic acid immobilizing the polypeptide to the solid support;
(iii) annealing the primer conjugated to the degradation moiety to the primer binding site; and
(iv) extending the primer conjugated to the degradation moiety using the nucleic acid immobilizing the polypeptide to the solid support as the template, thereby labeling the N-terminal amino acid with the nucleic acid label comprising the UMI.

### Claim 6 (depends on 4)

The method according to claim 4, wherein the labeling step (a) comprises:
(i) conjugating to the N-terminal amino acid a degradation moiety conjugated to a primer comprising a sequence which is complementary to the primer binding site of the nucleic acid immobilizing the polypeptide to the solid support;
(ii) annealing the primer conjugated to the degradation moiety to the primer binding site; and
(iii) extending the primer conjugated to the degradation moiety using the nucleic acid immobilizing the polypeptide to the solid support as the template, thereby labeling the N-terminal amino acid with the nucleic acid label comprising the UMI.

### Claim 7 (depends on 5, 6)

The method according to claim 5 or claim 6, wherein the degradation moiety comprises a phenylisothiocyanate (PITC) bearing a reactive group for conjugation to the nucleic acid comprising the cycle number barcode.

### Claim 8 (depends on 7)

The method according to claim 7, wherein the reactive group is a click-chemistry reactive group.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

The method according to any one of claims 1-8, wherein the degrading step (b) is performed under conditions comprising a Lewis acid in an aprotic solvent.

### Claim 10 (depends on 9)

The method according to claim 9, wherein the Lewis acid is BF3 etherate, BCl3, BBr3, Scandium(III) triflate, or any combination thereof.

### Claim 11 (depends on 9)

The method according to claim 9, wherein the Lewis acid is BF3 etherate.

### Claim 12 (depends on 9, 10, 11)

The method according to any one of claims 9-11, wherein the aprotic solvent is acetonitrile, N,N-dimethylformamide (DMF), dimethyl sulfoxide (DMSO), or any combination thereof.

### Claim 13 (depends on 12)

The method according to claim 12, wherein the degrading step (b) is performed under conditions comprising triethylamine acetate in N,N-dimethylformamide (DMF).

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

The method according to any one of claims 1 to 13, wherein one or more nucleic acids employed in step (a) and/or step (b) comprise non-natural nucleotides that stabilize the nucleic acids during degrading step (b).

### Claim 15 (depends on 14)

The method according to claim 14, wherein the non-natural nucleotides comprise 7-deazapurine nucleotides.

### Claim 16 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)

The method according to any one of claims 1 to 15, wherein at step (c), the primer comprising the barcode corresponding to the identity of the degraded N-terminal amino acid is conjugated to a binding moiety that specifically binds the degraded N-terminal amino acid, and wherein the annealing is dependent upon binding of the binding moiety to the degraded N-terminal amino acid.

### Claim 17 (depends on 16)

The method according to claim 16, wherein the binding moiety specifically binds a degraded N-terminal amino acid comprising a post-translational modification, and wherein the barcode indicates the identity of the degraded N-terminal amino acid and the post-translational modification.

### Claim 18 (depends on 16, 17)

The method according to claim 16 or claim 17, wherein the post-translational modification is phosphorylation, glycosylation, ubiquitination, nitrosylation, methylation, acetylation, or lipidation.

### Claim 19 (depends on 16, 17, 18)

The method according to any one of claims 16 to 18, wherein the binding moiety is a polypeptide.

### Claim 20 (depends on 19)

The method according to claim 19, wherein the polypeptide is an antibody.

### Claim 21 (depends on 16, 17, 18)

The method according to any one of claims 16 to 18, wherein the binding moiety is a small molecule or an aptamer.

### Claim 22 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21)

The method according to any one of claims 1 to 21, wherein the polypeptide to be sequenced is present in a protein sample isolated from a single cell.

### Claim 23 (depends on 22)

The method according to claim 22, wherein the method is a single-cell protein sequencing method performed on a plurality of polypeptides present in the protein sample.

### Claim 24 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23)

The method according to any one of claims 1 to 23, wherein the polypeptide to be sequenced is present in a protein sample isolated from a tissue sample.

### Claim 25 (depends on 24)

The method according to claim 24, wherein the tissue sample is a biopsy sample.

### Claim 26 (depends on 25)

The method according to claim 25, wherein the biopsy sample is a tumor biopsy sample.

### Claim 27 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23)

The method according to any one of claims 1 to 23, wherein the polypeptide to be sequenced is present in a protein sample isolated from a biological fluid.

### Claim 28

A composition comprising one or any combination of the following:
(a) UMI-functionalized solid supports,
(b) a degradation moiety bearing a reactive group for conjugation to a nucleic acid,
(c) a primer comprising a cycle number barcode,
(d) Edman degradation reagents,
(e) a conjugate comprising a primer conjugated to a binding moiety that specifically binds an amino acid,
(f) a conjugate comprising a primer conjugated to a binding moiety that specifically binds an amino acid bearing a post-translational modification, and
(g) nucleic acid sequencing adapters

### Claim 29 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27)

A kit comprising:
(a) one or any combination of the following reagents:
(i) UMI-functionalized solid supports,
(ii) a degradation moiety bearing a reactive group for conjugation to a nucleic acid,
(iii) a primer comprising a cycle number barcode,
(iv) Edman degradation reagents,
(v) a conjugate comprising a primer conjugated to a binding moiety that specifically binds an amino acid,
(vi) a conjugate comprising a primer conjugated to a binding moiety that specifically binds an amino acid bearing a post-translational modification, and
(vii) nucleic acid sequencing adapters; and
(b) instructions for using the one or any combination of reagents to perform the method of any one of claims 1 to 27.

### Claim 30 (depends on 29)

The kit of claim 29, wherein the degradation moiety comprises a PITC bearing a reactive group for conjugation to the primer comprising the cycle number barcode.

### Claim 31 (depends on 30)

The kit of claim 30, wherein the reactive group is a click-chemistry reactive group.

### Claim 32 (depends on 29, 30, 31)

The kit of any one of claims 29 to 31, wherein the Edman degradation reagents comprise a Lewis acid in an aprotic solvent.

### Claim 33 (depends on 32)

The kit of claim 32, wherein the Lewis acid is BF3 etherate, BCl3, BBr3, Scandium(III) triflate, or any combination thereof.

### Claim 34 (depends on 32)

The kit of claim 32, wherein the Lewis acid is BF3 etherate.

### Claim 35 (depends on 32, 33, 34)

The kit of any one of claims 32 to 34, wherein the aprotic solvent is acetonitrile, N,N-dimethylformamide (DMF), dimethyl sulfoxide (DMSO), or any combination thereof.

### Claim 36 (depends on 29, 30, 31, 32, 33, 34, 35)

The kit of any one of claims 29 to 35, wherein one or more of the nucleic acid-based reagents comprise non-natural nucleotides that stabilize the nucleic acids under Edman degradation conditions.

### Claim 37 (depends on 36)

The kit of claim 36, wherein the non-natural nucleotides comprise 7-deazapurine nucleotides.

### Claim 38 (depends on 29, 30, 31, 32, 33, 34, 35, 36, 37)

The kit of any one of claims 29 to 37, wherein the binding moiety is a polypeptide.

### Claim 39 (depends on 38)

The kit of claim 38, wherein the polypeptide is an antibody.

### Claim 40 (depends on 29, 30, 31, 32, 33, 34, 35, 36, 37)

The kit of any one of claims 29 to 37, wherein the binding moiety is a small molecule or an aptamer.
